Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma	B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-02-19		NCT04842877

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Daiichi Sankyo	144
The Lymphoma Academic Research Organisation	20

22 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
A.Z. Sint Jan AV	Bruges	Belgium	2
CH d'Avignon	Avignon	France	3
Ch de Bretagne Atlantique -	Vannes	France	1
CH de la Côte Basque	Bayonne	France	4
Ch Metropole Savoie - Site Chambery	Chambéry	France	2
CH Tourelle Peltzer	Verviers	Belgium	1
Chd de Vendee	La Roche-sur-Yon	France	2
CHU d'Estaing	Clermont-Ferrand	France	2
CHU de Dijon	Dijon	France	1
CHU de Montpellier	Montpellier	France	22
CHU Hôtel Dieu	Nantes	France	5
CHU Mont-Godinne	Yvoir	Belgium	1
CHU Pontchaillou	Rennes	France	3
Clinique Victor Hugo	Le Mans	France	13
Emmanuel Bachy	Pierre-Bénite	France	1
François Lemonnier	Créteil	France	1
Gh Region Mulhouse Et Sud Alsace	Mulhouse	France	1
Institut Bergonié	Bordeaux	France	53
Institut d'Hématologie de Basse Normandie	Caen	France	1
Institut Paoli Calmette	Marseille	France	4
Service des Maladies du Sang - CHRU de Lille	Lille	France	1
University Hospital Gent	Ghent	Belgium	11

Clinical trials